MYND Diagnostics will be initiating a clinical validation study on the use of its proprietary biomarker testing in Multiple Sclerosis diagnostics

VANCOUVER, BC, Nov. 18, 2021 /CNW/ – MYND LIFE SCIENCES INC. (“MYND” or the “Company”) (CSE: MYND) (OTC: MYNDF) is pleased to announce its wholly-owned subsidiary MYND DIAGNOSTICS INC. (“MYND Diagnostics“) has commenced clinical research on a testing procedure as an aid for diagnosing and monitoring Multiple Sclerosis (“MS“) utilizing the Company’s proprietary anti-inflammatory peptide (“MAP“) biomarker.

“According to the National Multiple Sclerosis Society, at this time no symptoms, physical findings or laboratory tests can, by themselves, determine if you have MS¹“, stated Dr. Lyle Oberg, MD CEO of MYND. “This makes MS such a challenging disease to diagnose; the wide variance of symptoms can make early detection difficult. It is our goal through MYND Diagnostics’ clinical validation study targeting MS to provide health care practitioners with an objective diagnostic aid to help discover MS earlier and monitor treatment progress or regression.”

MYND Diagnostics will be initiating a clinical validation of the MAP biomarker in MS by collecting known blood samples of MS patients and quantifying the presence of MAP against control samples. This validation is planned to start in first quarter 2022. The Company anticipates that, pending those results, a submission for FDA approval could take place as early as second half 2022 to prepare for commercialization and making the MAP Biomarker test available to the public through healthcare practitioners. The Company’s goal is to develop and refine a diagnostic protocol to monitor and potentially identify inflammatory diseases of the central nervous system such as Multiple Sclerosis. The Company’s aid to diagnosis test is intended to give health care providers an objective monitoring tool to improve patient outcomes by providing more tailored and efficacious treatments.

The global multiple sclerosis therapies market was valued at $22.99 billion in 2018, and is projected to reach $28.00 billion by 2026, registering a CAGR of 2.5% from 2019 to 2026.² Management’s view is that the total addressable market is substantial and existing diagnostic methods are outdated and ready for disruption. Management believes this affordable tool coupled with MYND Diagnostics’ proprietary intellectual property has the potential to revolutionize how central nervous system diseases are diagnosed and monitored around the globe.

MS currently affects approximately 2,800,000 people around the world, females far more often than males, and it is estimated that every 5 minutes, someone in the world is diagnosed with MS. Nearly 1,000,000 of those people are living in the United States³. Canada continues to have one of the highest rates of MS in the world, with over 90,000 people living with MS or 1 in every 400 people⁴.

ABOUT MYND LIFE SCIENCES INC.

MYND Life Sciences Inc., the parent company of MYND Diagnostics Inc., is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel psilocybin drug development, diagnostics and vaccines. The Company is advancing pharmaceuticals through rigorous science and clinical trials, while diligently patenting and safeguarding its intellectual property. For more information and to subscribe to the Company’s mailing list, please visit https://myndsciences.com/contact/.

CONTACT INFORMATION

MYND Life Sciences Inc.
Dr. Lyle Oberg, MD, CEO
Email: [email protected]
Web: www.myndsciences.com

Forward-Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this release.

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

None of the securities issued in connection with the Offering will be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

The Company will be initiating a clinical validation study on the use of its proprietary biomarker testing in Alzheimer’s Disease diagnostics

VANCOUVER, BC, Nov. 16, 2021 /CNW/ – MYND LIFE SCIENCES INC. (“MYND” or the “Company”) (CSE: MYND) (OTC: MYNDF) is pleased to announce its wholly-owned subsidiary MYND DIAGNOSTICS INC. (“MYND Diagnostics“) has commenced clinical research on a testing procedure for diagnosing and monitoring Alzheimer’s Disease (“AD“) utilizing the Company’s proprietary anti-inflammatory peptide (“MAP“) biomarker.

“Our research team has begun to research and explore the potential application of our proprietary MAP biomarker for use in the identification of Alzheimers disease”, stated Dr. Lyle Oberg, CEO of MYND. “The ability to make an early, accurate, dependable diagnosis in Alzheimer’s Disease patients thereby allowing for earlier intervention is a huge step forward in the fight against this terrible disease. We are extremely excited that the MAP biomarker has the potential to bridge that gap. The Company’s ultimate goal specific to diagnostics is to provide a cost-effective, easy to use diagnostic test kit that can be administered from anywhere with a dried blood spot. Helping families and health care practitioners with an effective tool for early diagnosis, monitoring and treatment for the millions impacted by this disease will be a significant innovation in central nervous system medicine”.

MYND Diagnostics will be initiating a clinical validation of the MAP biomarker in AD by collecting known blood samples of AD and quantifying the presence of MAP against control samples. This validation is planned to start in first quarter 2022. Pending those results, the Company anticipates that a submission for FDA approval could take place as early as second half 2022 to prepare for commercialization and making the MAP Biomarker available to the public through healthcare practitioners. The Company’s goal is to develop diagnostic test to monitor and potentially diagnose inflammatory diseases of the central nervous system such as Alzheimer’s Disease. The Company’s diagnostic test is intended to give health care providers an objective monitoring tool to improve patient outcomes by providing more tailored and efficacious treatments.

Approximately 44 million people worldwide live with AD or a related form of dementia.¹ It is the sixth-leading cause of death in the U.S., killing more people than breast cancer and prostate cancer combined.² Only approximately one in four people with the disease get diagnosed.³ Further, the Alzheimer’s disease diagnostics and therapeutics market was valued at USD 6.6 billion in 2020, and it is expected to reach approximately USD 9 billion in 2026, registering a CAGR of nearly 5.36% during the forecast period, 2021-2026.⁴

ABOUT MYND LIFE SCIENCES INC.

MYND Life Sciences Inc., the parent company of MYND Diagnostics Inc., is a medical biotech drug research and development company focused on neuro-pharmaceutical and novel psilocybin drug development, diagnostics and vaccines. The Company is advancing pharmaceuticals through rigorous science and clinical trials, while diligently patenting and safeguarding its intellectual property. For more information and to subscribe to the Company’s mailing list, please visit https://myndsciences.com/contact/.

CONTACT INFORMATION

MYND Life Sciences Inc.
Dr. Lyle Oberg, MD, CEO
Email: [email protected]
Web: www.myndsciences.com

Forward-Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this release.

Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

None of the securities issued in connection with the Offering will be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Post-traumatic stress disorder, or PTSD, is a common mental illness among veterans. According to the Department of Veteran Affairs, 11% to 30% of veterans who served in foreign wars experience PTSD, far higher than the estimated 6% of the general population. PTSD manifests in many ways, ranging from depression to chronic fatigue.

The FDA’s decision to approve Spravato, an esketamine nasal spray, to treat depression and suicidal ideations marked the beginning of a psychedelic revolution in mental healthcare. Researchers believe that ketamine could also play a role in treating other mental health conditions, including PTSD and its many symptoms.

Let’s take a look at ketamine’s promise in treating PTSD and how KetamineOne Capital Ltd. (NEO: MEDI) (OTC: KONEF) (FFT: MY0) (“Ketamine One” or the “Company”) aims to bring treatments to veterans and other sufferers of mental health conditions.

Ketamine Shows Promise

Ketamine has shown the potential to treat PTSD in several clinical studies. 

For example, a 2014 study found that intravenous ketamine was associated with significant and rapid reductions in PTSD symptom severity, compared with midazolam, when assessed 24 hours after infusion. In addition, researchers reported that the treatment was generally well-tolerated without persistent dissociative symptoms.

More recently, a 2021 study conducted by Mount Sinai researchers found that repeated infusions with ketamine over two weeks significantly reduced symptom severity in many patients while also helping minimize depression symptoms. While improvement occurred after just 24 hours, the benefit was “significantly greater” at two weeks and lasted ~30 days.

Bringing Treatments to Veterans

Ketamine infusion centers are becoming increasingly common across North America.

For example, Ketamine One (NEO: MEDI) (OTC: KONEF) (FFT: MY0) recently signed a non-binding letter of intent with Veteran Services USA to lease 5,000 sq. ft. of space over five years in Blue Island, Illinois, to provide ketamine-assisted therapies. Its goal is to create a first-of-its-kind healing experience for veterans who have PTSD.

“We are very proud to be part of an important project such as this with Veteran Services USA, which will allow KetamineOne to showcase its innovative approach to care and treatment by addressing veterans’ unique needs,” said Interim CEO Adam Deffett. “Our company sees an immediate need for its services and has a special opportunity to help.”

Part of a Broader Picture

Ketamine’s potential is just starting to be realized, and the Company plans to build a leading network of clinics.

 There are more than 200 active clinical trials involving ketamine in the United States, according to ClinicalTrials.gov. Researchers are evaluating the breakthrough drug to treat conditions like epilepsy, bipolar depression, postpartum depression, perinatal depression, cognitive dysfunction, autism spectrum disorder, and countless other conditions. 

In the meantime, Ketamine One (NEO: MEDI) (OTC: KONEF) (FFT: MY0) aims to consolidate medical clinics and become a North American leader in mental health treatments. Currently, the Company has 16 clinics across North America and acquired a contract research organization (CRO) to expand into the clinical side of the industry.

Looking Ahead

Ketamine has shown tremendous potential for treating PTSD, but that’s just scratching the surface of what’s possible.

Ketamine One’s (NEO: MEDI) (OTC: KONEF) (FFT: MY0) acquisition of KGK Science, a CRO, brings 24 years of experience across pharmaceuticals, cannabis, and emerging psychedelics. In conjunction with its network of clinics, the company is well-positioned to become a leader in conducting cutting-edge clinical research in the space.

For more information, visit the Company’s website or download their investor presentation.

Click here to receive an investor presentation and corporate updates

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Toronto, Ontario–(Newsfile Corp. – August 25, 2021) – PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the Company has entered into a Clinical Trial Agreement with The Johns Hopkins University (JHU) to conduct a clinical study comparing acute and enduring psychological and neural effects of N,N-Dimethyltryptamine (DMT) and an undisclosed, potently active comparator molecule. The principal investigator, Dr. Frederick S. Barrett, PhD, Associate Professor of Psychiatry and Behavioral Sciences, will be supported by Co-investigators Dr. Sandeep Nayak and Dr. Roland Griffiths; all from the JHU Center for Psychedelic and Consciousness Research.

The potential of psychedelic drugs to treat various neuropsychiatric indications is currently being explored in several human clinical trials. The dramatic mind-altering effects of these drugs is well known, and as such, a study volunteer’s expectancy may contribute to clinical outcomes. Such effects are considered classic study confounds and can lead to misinterpretation of efficacy signals. For example, this phenomenon was recently noted in a large, placebo-controlled study of LSD which found that those receiving LSD or placebo showed significant improvements in mood, anxiety, creativity and energy¹. To address this common study design limitation and to assess the neuropsychiatric impact of DMT more fully, the Company has sponsored the submission of an Investigational New Drug (“IND”) application to the U.S Food and Drug Administration (“FDA”) which aims to compare the effects of DMT with another potently psychotropic drug.

The first part of the planned study will examine dose effects of DMT and the other test article. During the second part of the study, healthy subjects will be exposed to a maximum tolerated dose of each drug (as defined in part 1 of the study). During both parts of the study, investigators will carefully characterize any acute and persisting subjective, affective, cognitive, and neural dose-dependent effects for both drugs being evaluated. Much debate exists around the relative potential benefits of micro vs macro-doses for psychedelic compounds. Using a highly controlled approach, the currently planned clinical trial will go some way to answering this important question. Employing an extensive battery of psychological assessment tools, coupled with state-of-the-art functional MRI and EEG the JHU researchers endeavour to develop a more fulsome understanding of how DMT acts in the brain of healthy volunteers; with the ultimate goal of being able to apply this knowledge in tailoring the treatment of serious neuropsychiatric conditions.

This clinical research collaboration builds upon PharmaDrug’s existing strategy of focusing on establishing a better understanding of the basic mechanisms by which DMT exerts its effects in the brain and elsewhere in the body. By supporting world class talent with distinct expertise in early discovery and clinical use the Company will be optimally positioned to identify novel applications for DMT and unlock its full therapeutic potential. The Company intends to become a leader in advancing DMT as a prescription pharmaceutical, and as previously reported, is the first organization to receive orphan drug designation by the U.S. FDA for DMT in the prevention of ischemia-reperfusion injury in patients undergoing solid organ transplantation, which includes the liver, kidney, heart, and lungs. As a further example of PharmaDrug’s commitment to DMT development, the Company recently entered into a sponsored research agreement with the Terasaki Institute to evaluate the potential of novel DMT delivery systems for the treatment of primary open angle glaucoma, one of the leading causes of vision loss worldwide.

Daniel Cohen, CEO of PharmaDrug commented: “We are excited to collaborate and support Dr. Frederick Barrett to better understand DMT and its potential. The JHU Center for Psychedelic and Consciousness Research is a global leader in psychedelics clinical research, and we are very grateful to partner with them to achieve our objectives in expanding our pharmaceutical product pipeline for novel uses and delivery forms of DMT to treat unmet medical needs.”

Under the terms of the agreement, the Company has an exclusive option to obtain worldwide, royalty-bearing commercialization license to all rights, title, and interest that JHU may have or obtain in any invention that results from the clinical study.

About PharmaDrug Inc.

PharmaDrug is a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs. The Company owns 80% of Pharmadrug Production GmbH, a German medical cannabis distributor, with a Schedule I European Union narcotics license and German EuGMP certification allowing for the importation and distribution of medical cannabis to pharmacies in Germany and throughout the EU. The Company also owns 100% of Super Smart, a Dutch company building a modern adult use psychedelic retail business with an elevated and educational focus. PharmaDrug recently acquired Sairiyo Therapeutics, a biotech company that specializes in researching and reformulating established natural medicines with a goal of bringing them through regulatory and research driven clinical trials.

For further information, please contact:

Daniel Cohen, Chairman and CEO
[email protected]
(647) 202-1824

Caution Regarding Forward-Looking Information:

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “potential”, “aim” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on PharmaDrug Inc. (the “Company”) current belief or assumptions as to the outcome and timing of such future events. Forward-looking information is based on reasonable assumptions that have been made by the Company at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Company’s management’s discussion and analysis for the period of March 31, 2021 (“MD&A”), dated May 31, 2021, which is available on the Company’s profile at www.sedar.com.

This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.

The Company’s securities have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or “U.S. Persons”, as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful.

References:

1) Szigeti B, Kartner L, Blemings A, Rosas F, Feilding A, Nutt DJ, Carhart-Harris RL, Erritzoe D. Self-blinding citizen science to explore psychedelic microdosing. Elife. 2021 Mar 2;10:e62878. doi: 10.7554/eLife.62878. PMID: 33648632; PMCID: PMC7925122.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Der nordamerikanische Markt für psychedelische Medikamente wird vorraussichtlich bis 2027 6.85 Milliarden USD erreichen, nach Daten der Data Bride Market Research, das entspricht einer jährlichen Wachstumsrate von 16.3%. Nach der Genehmigung von Johnson & Johnsons (NYSE: jnj) SPRAVATO Nasenspray für behandlusngsresistente Depressionen und zwei Breakthrough Therapie Bezeichnungen, sind Unternehmen, die Kapital beschaffen, um die  Multi-Milliarden-Dollar Märkte der psychischen Gesundheit zu revolutionieren.

Werfen wir einen Blick auf den Vormarsch psychedelischer Therapien, ihr Potenzial zur Behandlung, die massiven Märkte der psychischen Gesundheit und warum MagicMed Industries Inc. gut positioniert ist, mit seinem einzigartigen Buisnessmodell von dem entstehenden Markt zu profitieren.

Psychedelika gehen Mainstream

Psychedelika haben sich schnell von Randprodukypten zum Mainstream in Forschung und Entwicklung entwickelt. Das Imperial College of London, die University of California-Berkeley und Johns Hopkins haben alle psychedelische Forschungszentren etabliert, während die Food-and Drug Administration (FDA) den Status einer Breakthrough Therapie an zwei Psychedelika in aktiven klinischen Studien vegeben hat. Neben Forschung und Entwicklung haben die Kapitalmärkte einen unstillbaren Appetit für psychedelische Gelegenheiten gezeigt. Compass Pathways Inc. (NASDAQ: CMPS) hat sich nach seinem Börsengang an der NASDAQ verdoppelt und erreichte eine Marktkapitalisierung von mehr als eine Milliarde Dollar trotz des Anfangsstadiums seiner Bemühungen.

Die Kombination von Forschungsinteressen und Kapital generiert den perfekten Sturm, der nötig ist, um Millionen von Menschen, die an psychischen Problemen leiden, zu helfen und den

Markt für psychische Gesundheit zu transformieren. Diese Märkte im Wert von Milliarden von Dollar pro Jahr sind mit herkömmlichen Pharmazeutika und anderen Behandlungsmöglichkeiten unterversorgt.

Klicken Sie hier, um weitere Informationen zu Investitionen in Psychedelika zu erhalten

Massive Märkte für geistige Gesundheit

Mehr als ein Viertel der Amerikaner über 18 Jahren leiden unter einer diagnostizierbaren Störung der psychischen Gesundheit pro Jahr und ungefähr 17.3 Millionen Erwachsene haben mindestens eine heftige depressive Phase durchgemacht, laut Johns Hopkins. Tatsächlich sind  psychische Störungen eine der Top-Ursachen für Behinderung in etablierten Volkswirtschaften weltweit.

Psychedelika haben einen einzigartigen Wirkmechanismus, der eine wichtige Rolle bei der Behandlung einer große Anzahl dieser psychiatrischen Erkrankungen spielen könnte. Während Antidepressiva und andere Medikamente der psychischen Gesundheit seit geraumer Zeit angewandt werden und Milliarden von Dollar Umsatz pro Jahr generieren, ist ihre Wirksamkeit für die Mehrheit der Patienten fraglich.

Zum größten Potenzial für Psychedelikamärkte gehören:

Über diese Märkte hinaus gibt es eine Vielzahl von medizinischen Bereichen, die von  herkömmlichen Therapeutika unterversorgt sind und in denen Psychedelika eine wichtige Rolle spielen könnten. Aufkommende Forschung legt nahe, dass Psychedelika einen einzigartigen Wirkmechanismus bieten, der sich von konventionellen Behandlungen im Bereich psychischer Gesundheit unterscheidet und sichere permanente Alternativen bietet.

In Psychedelika investieren

Eine wachsende Zahl öffentlicher und privater Unternehmen zielt auf den psychedelischen Bereich ab, beispielsweise Compass Pathways Inc. (NASDAQ: CMPS) und Red Light Holland Corp (CSE: TRIP). Während viele dieser Unternehmen klinische Studien mit dem Ziel der Entwicklung anerkannter Pharmazeutika durchführen, haben andere einen auf dem Markt einzigartigen Ansatz. MagicMed Industries zielt darauf ab, führend in der Entwicklung neuer psychedelischer Molekülderivate zu werden. Während Psilocybin und andere natürlich vorkommenden psychedelische Moleküle nicht patentierbar sind, können Derivate verändert werden, um spezifische Ziele (z.B. weniger psychoaktive Effekte) zu erfüllen und Pharmazeutik-Unternehmen bessere Vermarktung zu ermöglichen.

Klicken Sie hier, um weitere Informationen zu Investitionen in Psychedelika zu erhalten

Das Unternehmen baut die Psybrary auf, in der sich eine Reihe psychedelischer Moleküle befinden, deren Lizenzen es an pharmazeutische oder Biotechnologieunternehmen vergibt. Durch die Lizenzierung der Moleküle, die das Unternehmen plant, generiert es Zahlungen auf der Grundlage klinischer Meilensteine und laufender Lizenzgebühren für jedes anerkannte pharmazeutische Produkt, was hohe Margen und wiederkehrenden Umsatz schafft. Zusätzlich zu den attraktiven Einnahmequellen haben Aktionäre Zugriff auf eine vielfältige Auswahl an Partnern, die eine breite Aufstellung in der Branche erlauben. Hoffnungen des Managements, 2020 erste Partner zu finden, werden zu positivem Cashflow  2021 und möglicherweise sogar zu diversifizieren Konsumgütern im Jahre 2022 führen.

Blick in die Zukunft

Die Psychedelikaindustrie könnte einige Segmente des Marktes für psychische Gesundheit mit Milliarden von Dollar Jahresumsatz nachhaltig verändern. Während viele Unternehmen einen klinische Ansatz auf dem Markt verfolgen, zielt MagicMed Industries darauf ab, ein führendes Unternehmen in der Entwicklung psychedelischer Derivat-Moleküle zu werden, deren Lizenzen es an pharmazeutische Unternehmen vergibt.

Investoren sollten das Unternehmen im Auge behalten, während es sich anschickt, im ersten oder zweiten Quartal des nächsten Jahres an die Börse zu gehen.

Weitere Informationen finden Sie auf der Website des Unternehmens oder indem Sie die Präsentation für Investoren downloaden.

Kontakt von MagicMed:

Beziehungen mit den Investoren

[email protected]

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.